275 related articles for article (PubMed ID: 24683373)
1. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.
Alkhouri N; McCullough AJ
Gastroenterol Hepatol (N Y); 2012 Oct; 8(10):661-8. PubMed ID: 24683373
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.
Jayakumar S; Harrison SA; Loomba R
Curr Hepatol Rep; 2016 Jun; 15(2):86-95. PubMed ID: 27795938
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.
Pearce SG; Thosani NC; Pan JJ
Biomark Res; 2013 Feb; 1(1):7. PubMed ID: 24252302
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests.
Fishman J; O'Connell T; Parrinello CM; Woolley JJ; Bercaw E; Charlton MR
J Health Econ Outcomes Res; 2024; 11(1):32-43. PubMed ID: 38370007
[No Abstract] [Full Text] [Related]
8. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
11. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
12. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
Wieckowska A; McCullough AJ; Feldstein AE
Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
[TBL] [Abstract][Full Text] [Related]
14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
15. Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores.
Wu Y; Yang X; Morris HL; Gurka MJ; Shenkman EA; Cusi K; Bril F; Donahoo WT
JMIR Med Inform; 2022 Jun; 10(6):e36997. PubMed ID: 35666557
[TBL] [Abstract][Full Text] [Related]
16. Markers in nonalcoholic steatohepatitis.
Armutcu F; Akyol S; Ucar F; Erdogan S; Akyol O
Adv Clin Chem; 2013; 61():67-125. PubMed ID: 24015600
[TBL] [Abstract][Full Text] [Related]
17. Pathology of nonalcoholic steatohepatitis.
Brunt EM
Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
[TBL] [Abstract][Full Text] [Related]
18. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
Papatheodoridi M; Cholongitas E
Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
